Later-Line Choices for Patients With Metastatic Breast Cancer

During a live virtual event, Joyce O'Shaughnessy, MD, discussed treatment options for a patient with metastatic triple-negative breast cancer whose disease recurred 8 months after receiving adjuvant therapy.

During a live virtual event, Joyce O'Shaughnessy, MD, discussed participants' experiences with the tolerability of sacituzumab govitecan in patients with metastatic triple-negative breast cancer. The participants also discussed their approaches to molecular testing for biomarkers at the time of disease relapse or progression.

During a live virtual event, Sara Tolaney, MD, discussed the results of the ASCENT trial of sacituzumab govitecan in patients with triple-negative breast cancer.

During a live virtual event, Sara Tolaney, MD, MPH, discussed the common issue of neutropenia in patients with triple-negative breast cancer who received sacituzumab govitecan in the ASCENT trial and in her clinical practice.

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with BRCA and PD-L1 negative, metastatic triple-negative breast cancer. Vote in the polls on what you would have chosen if this was your patient.

During a live virtual event, Rita Nanda, MD, discussed the choice of therapy for a patient whose metastatic triple-negative breast cancer recurred after adjuvant chemotherapy with paclitaxel.

During a live virtual event, Rita Nanda, MD, discussed with participants how to address toxicities of sacituzumab govitecan and how to treat a patient who progresses after receiving this agent.

During a Targeted Oncology case-based roundtable event, Elizabeth Ann Mittendorf, MD, discussed with participants their choice of treatment after progression for a patient with triple-negative breast cancer treated with adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel. This is the first of 2 articles based on this event.

During a live virtual event, Elizabeth Ann Mittendorf, MD, PhD, discussed the case of a patient with triple-negative breast cancer whose disease progressed following adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel, then frontline gemcitabine and carboplatin. This is the second of 2 articles based on this live event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed with participants the management of neutropenia and other toxicities associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed adverse event management in patients treated with sacituzumab govitecan for triple-negative breast cancer and other therapy options. This is the second of 2 articles based on this event.

Ruta D. Rao, MD, discussed the trial design and final efficacy results of the ASCENT trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

Ruta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth A. Mittendorf, MD, PhD, discussed the TROPiCS-02 trial of sacituzumab govitecan for patients with hormone receptor–positive, HER2-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth Mittendorf, MD, discussed how antibody-drug conjugates fit into the treatment algorithm for patients with advanced breast cancers.

In the first article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on what factors influence sequencing treatment for patients with estrogen receptor positive advanced breast cancer.

In the second article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on the practice-changing use of sacituzumab govitecan and trastuzumab deruxtecan for patients with advanced breast cancer.

In the first article of a 2-part series, Aditya Bardia, MD, MPH, explains how recent survival outcomes with sacituzumab govitecan impressed physicians treating patients with metastatic breast cancer.

In the second article of a 2-part series, Aditya Bardia, MD, MPH, discusses the favorable toxicity profile of sacituzumab govitecan for patients with metastatic breast cancer and how he handles neutropenia through the course of treatment.

During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.

During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.